Radar · Life Sciences in North Carolina
Best Life Sciences Companies in North Carolina, United States
The 553 best Life Sciences companies in North Carolina, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: BioCryst.
By Rohit KhannaTrends & Stories
553companies tracked
$8.3Bdisclosed funding
0unicorns
289have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × NORTH CAROLINA
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
156kcombined LinkedIn audience
42%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in North Carolina
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Areteia Developer of therapeutics for eosinophilic asthma | $425M | 28 mo ago | Series A | 19 | Jorge Bartolome CEO | Top 50M | — | — |
| 2 | Sprout Pharmaceuticals Developer of drugs for hypoactive sexual desire disorder in women | $175M | 18 mo ago | Acquired | 31 | — | Top 50M | — | — |
| 3 | Metabolon Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine | $173M | 16 mo ago | Series H | 189 189 → 203 (+7%) | — | Top 5M | 400 patents Metabolomics-based biomarker discovery and diagnostic assays for metabolic and inflammatory diseases. | — |
| 4 | Pairwise Provider of gene editing technology for climate-resilient, nutritious, and sustainable crops | $155M | 21 mo ago | Series C | 163 | Tom Adams CEO | Top 10M | — | 1 internship · 1 partnership · 1 award |
| 5 | Precision BioSciences Developer of gene editing therapies to treat rare genetic diseases 57Product top 19%Funding top 21%Moat top 32%Patents top 36% All 11 signals ▾Producttop 19% Fundingtop 21% Moattop 32% Patentstop 36% Newstop 38% Markettop 39% Techtop 41% Innovationtop 42% Growthbottom 47% Globalbottom 42% Fin. healthbottom 39% Product: 3 distinct product lines · Company stage: Public Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $136M | 3 mo ago | Public | 236 | — | Top 10M | 68 patents Therapeutic genome editing using engineered meganucleases and engineered T‑cell therapies | 1 launch |
| 6 | Slate Medicines Developer of therapeutics for the treatment of migraine and other headache disorders 53Funding top 20%Talent bottom 49%Global bottom 48% All 3 signals ▾Fundingtop 20% Talentbottom 49% Globalbottom 48% Funding: Raised $130M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 53/100 | $130M | 3 mo ago | Series A | — | Neil Buckley Co-Founder & CEO | — | — | — |
| 7 | Bryn Pharma Developer of nasal based epinephrine for anaphylaxis 10Funding top 26%Talent bottom 49%Global bottom 29%News bottom 24% All 6 signals ▾Fundingtop 26% Talentbottom 49% Globalbottom 29% Newsbottom 24% Marketbottom 20% Techbottom 17% Funding: Raised $123M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 10/100 | $123M | 14 mo ago | Series C | 10 | David Dworaczyk Retired CEO: Corporate Advisor/Consultant to Bryn Pharma | Top 50M | — | — |
| 8 | Baebies Provider of diagnostic products for pediatrics | $94M | 9 mo ago | Series C | 133 133 → 73 (-45%) | Richard West Co-Founder & CEO | Top 10M | 56 patents Rapid microfluidic PCR and point‑of‑care diagnostic platforms for biochemical assays | 3 launchs |
| 9 | Xilis Developer of drug discovery and precision therapy platform for oncology 53Patents top 21%Moat top 21%Innovation top 22%Funding top 26% All 9 signals ▾Patentstop 21% Moattop 21% Innovationtop 22% Fundingtop 26% Talentbottom 49% Marketbottom 46% Globalbottom 42% Techbottom 29% Newsbottom 22% Patents: 97 patents matched (strict assignee match) · 96 filings since 2022 vs 1 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $89M | 14 mo ago | Series B | 72 | Hans Clevers Co-Founder | Top 50M | 97 patents Micro-organosphere generation, manipulation, and drug testing via advanced microfluidic platforms | — |
| 10 | Atsena Therapeutics Developer of gene therapies for the treatment of ocular diseases | $88M | 9 mo ago | Series C | 23 23 → 49 (+113%) | Shannon Boye Founder & Director | Top 5M | — | 1 partnership |
| 11 | Tolerance Bio Developer of thymus-based therapies for immune-mediated diseases to increase healthspan | $37M | 17 mo ago | Seed | — | Holger Russ Scientific Co-Founder | — | — | — |
| 12 | 410 Medical Provider of rapid infusion system for critically ill patients | $37M | 15 mo ago | Series B | 33 | Mark Piehl Co-Founder & CMO | Top 10M | — | — |
| 13 | Aer Therapeutics Developing an inhaled approach to treat lung disease with excess mucus and mucus plugs | $36M | 16 mo ago | Series A | 8 | John Fahy Founder | — | — | — |
| 14 | T3D Therapeutics Developer of therapeutics for neurodegenerative diseases | $33M | 10 mo ago | Series B | 14 | John Didsbury Founder and CEO | — | — | — |
| 15 | Incyclix Bio A next-generation cell cycle control company advancing precision treatments for cancer 21Funding top 25%Talent top 28%Moat top 39%Tech bottom 31% All 6 signals ▾Fundingtop 25% Talenttop 28% Moattop 39% Techbottom 31% Globalbottom 29% Marketbottom 20% Funding: Raised $30.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $30M | 2 mo ago | Series B | 6 | Patrick Roberts Co-Founder & CEO | Top 50M | — | — |
| 16 | Pneuma Respiratory Developer of pulmonary drug delivery solutions | $29M | 16 mo ago | Series B | — | Eric Hunter CEO | — | 237 patents Advanced aerosol and droplet drug delivery systems for respiratory and nasal therapeutics | — |
| 17 | Levee Medical Developer of urological devices for post-prostatectomy | $27M | 3 mo ago | Series B | 3 | Bruce Choi Founder & CTO | — | — | — |
| 18 | CytexOrtho Developer of bio-artificial devices to treat musculoskeletal diseases 32Funding top 38%Talent top 38%Growth top 41%Fin. health bottom 45% All 7 signals ▾Fundingtop 38% Talenttop 38% Growthtop 41% Fin. healthbottom 45% Techbottom 41% Globalbottom 32% Marketbottom 24% Funding: Raised $24.4M across 17 rounds · 17 rounds over 4 yrs (4.2/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 32/100 | $24M | 14 mo ago | Seed | 10 | Frank Moutos Co-Founder | Top 50M | — | — |
| 19 | Opus Genetics Developer of gene therapies to treat retinal degenerative diseases 42Patents top 29%Funding top 30%Moat top 32%Innovation top 34% All 11 signals ▾Patentstop 29% Fundingtop 30% Moattop 32% Innovationtop 34% Talenttop 38% Growthtop 47% Techtop 50% Newstop 50% Globalbottom 36% Marketbottom 31% Fin. healthbottom 28% Patents: 26 patents matched (strict assignee match) · 26 filings since 2022 vs 0 in 2017-21 Funding: Raised $23.5M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $24M | 10 mo ago | Public | 14 | Jason Menzo Co-Founder | Top 10M | 26 patents Ophthalmic alpha‑adrenergic antagonist drugs for mydriasis, presbyopia, and AMD treatment | — |
| 20 | Reactive Biosciences Developer of boron-based medicines for various disease conditions | $23M | 16 mo ago | Series A | — | Julie Grant CEO | — | — | — |
| 21 | Glycan Therapeutics Developer of glycan-based therapeutics for coagulation and thrombo inflammation | $23M | 14 mo ago | Funding Raised | 4 | Yongmei Xu Co-Founder
| Top 50M | — | — |
| 22 | Mucommune R&D firm advancing immunology, drug delivery, and mucosal biology innovations 9Funding top 33%Moat bottom 49%Talent bottom 45%Patents bottom 35% All 7 signals ▾Fundingtop 33% Moatbottom 49% Talentbottom 45% Patentsbottom 35% Globalbottom 35% Marketbottom 20% Innovationbottom 17% Funding: Raised $19.4M across 13 rounds · 13 rounds over 10 yrs (1.3/yr) Moat: Editorial + unicorn rating 1/10 · IP moat: 6 patents rank vs industry peers · Fliar Intelligence Index 9/100 | $19M | 9 mo ago | Funding Raised | 12 | Sam Lai Founder | — | 6 patents Patents concentrated in chemistry & materials | — |
| 23 | GeneCentric Developer of diagnostics for cancer classification and treatment | $19M | 12 mo ago | Series C | 19 | — | Top 50M | — | — |
| 24 | Ten63 Developer of therapeutics for undruggable targets 21Talent top 28%Funding top 32%Moat top 35%News top 44% All 7 signals ▾Talenttop 28% Fundingtop 32% Moattop 35% Newstop 44% Globalbottom 39% Techbottom 26% Marketbottom 24% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $18.3M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $18M | 3 mo ago | Series A | 10 | Mark Hallen Co-Founder & CTO | Top 50M | — | — |
| 25 | Xemed Developing inhaled diagnostic agents for respiratory diseases using hyperpolarized gas MRI | $18M | 16 mo ago | Funding Raised | 10 | William Hersman Founder & CEO | — | 13 patents Patents concentrated in electrical & electronics | — |
| 26 | Perfusio Developer of the blood-flowing imaging device for surgeries | $16M | 19 mo ago | Series A | 6 | Monte Tucker CEO | — | — | — |
| 27 | Cerulean Scientific Developer of an implantable medical devices for vascular patients | $14M | 11 mo ago | Funding Raised | — | Lora Allemeier CEO | — | — | — |
| 28 | Ascent Bio-Nano Technologies Innovating acoustofluidic technologies for research, diagnostics, and therapeutics with social impact | $14M | 9 mo ago | Funding Raised | 2 | Lin Wang Co-Founder & CEO | — | — | — |
| 29 | Deep Blue Medical Advance Developer of hernia mesh devices for treating hernia | $13M | 9 mo ago | Series A | 12 | — | — | — | — |
| 30 | Inanovate Provider of multiplexed protein quantification platform for clinical diagnostics and research | $11M | 14 mo ago | Series C | 11 | David Ure Chairman & Founder | — | 30 patents High-throughput immunoassay platforms for serology and cancer biomarker detection | — |
| 31 | Doron Therapeutics Provider of therapeutics for orthopedic indications | $11M | 18 mo ago | Series A | — | Alessandra Pavesio Co-Founder & CEO | — | — | — |
| 32 | NeuroGT Developer of gene therapies for rare neurogenetic diseases | $10M | 9 mo ago | Funding Raised | — | Haiyan Fu Founder | — | — | — |
| 33 | Evecxia Therapeutics Developing 5-HTP drugs to amplify serotonin for mental illness treatment | $10M | 9 mo ago | Series A | 10 | Marc Caron Co-Founder | Top 10M | — | — |
| 34 | Sonovascular eveloper of a medical device to treat arterial and venous diseases | $8M | 4 mo ago | Series A | 8 | Daniel Estay Founder & CEO | Top 50M | 7 patents Intravascular ultrasound catheter technology for enhanced imaging and therapeutic delivery. | — |
| 35 | Vascular BioSciences Vascular BioSciences: Pioneering targeted therapies, interventional devices, and molecular diagnostics | $8M | 14 mo ago | Funding Raised | 24 | David Mann CEO & Chairman | — | — | — |
| 36 | Create Wellness Provider of creatine monohydrate gummies to support overall well-being | $7M | 2 mo ago | Series B | 8 | Sienna McCormick Co-Founder & Co-CEO | Top 500k | — | 1 launch |
| 37 | Celldom Developer of single cell analysis device | $6M | 14 mo ago | Seed | 9 | Zachary Forbes Founder & CEO | — | 8 patents Microfluidic single-cell assay platforms for drug screening and barcoded particle analysis | — |
| 38 | SoyMeds Biotech research: developing soybean seed-based therapeutics for disease treatment | $6M | 14 mo ago | Funding Raised | 5 | — | — | 3 patents Plant-based recombinant protein production for edible vaccines and therapeutic proteins | — |
| 39 | Altis Biosystems Provider of invitro platform for drug testing | $5M | 6 mo ago | Seed | 29 | Scott Magness Co-Founder | Top 50M | — | — |
| 40 | Amissa Developer of a wearable-based data collection solutions for the prediction, early identification, and… | $5M | 10 mo ago | Funding Raised | 7 | Jon Corkey Founder & CEO | Top 10M | — | — |
| 41 | Alleviate Health Provider of AI-powered platform for clinical research participant recruitment workflows | $4M | 8 mo ago | Seed | — | Saathvik Boompelli Co-Founder | — | — | — |
| 42 | EpiCypher Provider of epigentic kits, reagents and assays for research purpose | $3M | 9 mo ago | Series A | 43 | — | Top 5M | 66 patents Chromatin profiling tools: nucleosome barcoding, modification quantification, and high‑throughput assays | 1 partnership |
| 43 | inSoma Bio Provider of protein-based biomaterials for tissue engineering and regenerative medicine | $3M | 6 mo ago | Seed | 6 | Stefan Roberts Co-Founder & CEO | Top 50M | — | — |
| 44 | SelSym Developer of therapeutics for hemostasis and wound healing | $3M | 9 mo ago | Funding Raised | 5 | — | — | — | — |
| 45 | Reselute Developer of solutions for the treatment of orthopedic-related infections | $3M | 12 mo ago | Seed | 5 | Jake Donovan Co-Founder and Head of Product Development | — | 3 patents Orthopedic intramedullary fixation devices with integrated drug‑eluting capabilities | — |
| 46 | Galaxy Diagnostics PCR-based Human and Animal testing for vector-borne diseases | $3M | 14 mo ago | Series A | 15 | — | Top 5M | — | — |
| 47 | InnovaPrep Sample preparation tools for microbiology research | $3M | 6 mo ago | Series A | 37 37 → 23 (-38%) | Dave Alburty CEO | Top 50M | 111 patents Disposable fluid-path devices for concentrating biological particles in liquids and aerosols | — |
| 48 | Inhalon Biopharma Developing inhaled antibody treatments for acute respiratory infections, a clinical-stage biotechnology… | $2M | 9 mo ago | Seed | 8 | — | — | — | — |
| 49 | Adaptin Bio Developer of drug delivery platform for brain diseases | $1M | 5 mo ago | Public | — | Michael Roberts Co-Founder & CEO | — | — | — |
| 50 | Vogenx Developer of therapeutics for the treatment of serious metabolic and gastrointestinal diseases | $750K | 6 mo ago | Funding Raised | — | James Green Chief Executive Officer | — | 9 patents Patents concentrated in health & consumer products | — |
Top 12 Life Sciences companies in North Carolina
#1
Public · Durham, North Carolina · founded 2006 · 236 employees$135.7Mraised▾
Public · Durham, North Carolina · founded 2006 · 236 employees
Developer of gene editing therapies to treat rare genetic diseases. The company utilizes novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination. The company's pipeline include therapies for Hepatitis B, duchenne muscular dystrophy, and more.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Product
top 19%Funding
top 21%Moat
top 32%Patents
top 36%News
top 38%Market
top 39%Product: 3 distinct product lines · Company stage: Public
Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Moat: Editorial + unicorn rating 6/10 · IP moat: 68 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 15.5% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Post IPO$7.5M
- Jun 2022Post IPO$75M
- Mar 2019Conventional Debt$39.5M
- Jun 2018Series B$110M
Investors
NIST, NIH, North Carolina, Treasury, VenBio, Baxter
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#2
Series A · Raleigh, North Carolina · founded 2026$130Mraised▾
Series A · Raleigh, North Carolina · founded 2026
Developer of therapeutics for the treatment of migraine and other headache disorders. The company is focused on developing next generation therapeutics targeting PACAP for the treatment and prevention of migraine and other headache disorder
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 20%Talent
bottom 49%Global
bottom 48%Funding: Raised $130M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Feb 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Global: Investors from 1 country beyond United States
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Feb 2026Series A$130M
Founders & team
Investors
RA Capital Management, Forbion, Foresite Capital
#3
Series B · Durham, North Carolina · founded 2020 · 6 employees$30Mraised▾
Series B · Durham, North Carolina · founded 2020 · 6 employees
A next-generation cell cycle control company advancing precision treatments for cancer. The company’s lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor entering clinical development and has therapeutic targets across many tumor types, including ovarian, breast, and lung cancers.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 25%Talent
top 28%Moat
top 39%Tech
bottom 31%Global
bottom 29%Market
bottom 20%Funding: Raised $30.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series B (Apr 2026)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Apr 2026Series B$5M
- Aug 2025Series B$11.2M
- Mar 2022Series B$30M
Founders & team
Investors
Boxer Capital, RA Capital Management, Eshelman Ventures, Lilly, Pharmacosmos, Cape Fear BioCapital
#4
Series B · Durham, North Carolina · founded 2021 · 3 employees$27.4Mraised▾
Series B · Durham, North Carolina · founded 2021 · 3 employees
Developer of urological devices for post-prostatectomy. It offers VORO urological scaffold a bioresorbable device for urinary incontinence in radical prostatectomy patients. It optimizes and reduces complications associated with surgical treatment.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Feb 2026Series B$12M
- Oct 2025Conventional Debt$12.5M
- Feb 2025Series B$14M
- Sep 2023Series A$4.3M
Founders & team
#5
Series C · Durham, North Carolina · founded 2013 · 133 employees$93.8Mraised▾
Series C · Durham, North Carolina · founded 2013 · 133 employees
Provider of diagnostic products for pediatrics. Its proprietary platform the SEEKER is a microfluidic instrument that enables the high-throughput measurement of enzymatic activity in dried blood specimens of newborn babies. It also has another product the FINDER which is an automated screening solution for critical pediatric tests.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 4.4% of this cohort's audience
Activity: 3 product launches announced in 12 mo
Funding rounds
- Sep 2025Series C$2M
- Feb 2025Grant (prize money)$1.5M
- Apr 2023Grant (prize money)$1.3M
- May 2022Grant (prize money)$2M
Founders & team
Investors
BOE Technology Group, CARB-X, NCBiotech, Duke University, Duke Angel Network, Charleston Angel Partners
Tech stack
BootstrapCloudflareCloudflare Bot ManagementElfsightFlickityFresco
#6
Series C · Durham, North Carolina · founded 2020 · 23 employees$88Mraised▾
Series C · Durham, North Carolina · founded 2020 · 23 employees
Developer of gene therapies for the treatment of ocular diseases. It leverages AAV.SPR, a novel spreading capsid, to evaluate best-in-class gene therapy candidate, ATSN-201, for X-linked retinoschisis a rare pediatric disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 14k LinkedIn followers — 8.9% of this cohort's audience
Activity: 1 partnerships (incl. patients and investigators) announced in 12 mo
Funding rounds
- Sep 2025Grant (prize money)$870.7K
- Mar 2025Series C$150M
- Oct 2023Series B$24.5M
- Dec 2020Series A$55M
Founders & team
Investors
Hatteras Venture Partners, Foundation Fighting Blindness, Sofinnova Investments, Abingworth, Lightstone Ventures, RD Fund
Tech stack
CloudflareCloudflare Bot ManagementCookieyesDocusignGodaddyGoogle Font Api
#7
Series A · Durham, North Carolina · founded 2019 · 10 employees$18.3Mraised▾
Series A · Durham, North Carolina · founded 2019 · 10 employees
Ten63 is a developer of drugs that target undruggable protein targets. The company is developing therapeutics through its platform called COPPER that uses proprietary AI technology and physical models to explore the protein chemical space and screen a large dataset of molecules to identify binding sites.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Talent
top 28%Funding
top 32%Moat
top 35%News
top 44%Global
bottom 39%Tech
bottom 26%Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Funding: Raised $18.3M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Series A (Feb 2026)
Moat: Editorial + unicorn rating 7/10 · 3 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers — 2.9% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Principal Scientific Engineer
Funding rounds
- Feb 2026Series A—
- May 2023Series A$15.9M
- Jan 2021Seed$2.1M
- 2019Seed$250K
Founders & team
Investors
Hatteras Venture Partners, Morpheus Ventures, SOSV, Draper, Alexandria, Sigma Group
#8
Series B · Chapel Hill, North Carolina · founded 2022 · 8 employees$7.3Mraised▾
Series B · Chapel Hill, North Carolina · founded 2022 · 8 employees
Provider of creatine monohydrate gummies to support overall well-being. The company is offering Creatine gummies that can improve muscle performance, particularly during high-intensity, short-duration exercises.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 10k LinkedIn followers — 6.5% of this cohort's audience
Activity: 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Series B$20M
- Jul 2024Series A$7.3M
Founders & team
Investors
Unilever Ventures, ACG, Impact Capital
#9
Series C · Raleigh, North Carolina · founded 2018 · 10 employees$123Mraised▾
Series C · Raleigh, North Carolina · founded 2018 · 10 employees
Bryn Pharma has developed nasal based epinephrine for anaphylaxis. The company has developed a portable epinephrine auto-injector that can also be used as an intranasal epinephrine delivery system to treat allergic reactions or an anaphylactic reaction.
Fliar Intelligence Index™ 10how this company ranks against its industry peers
Funding
top 26%Talent
bottom 49%Global
bottom 29%News
bottom 24%Market
bottom 20%Tech
bottom 17%Funding: Raised $123M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) · Last round Series C (Apr 2025)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Global: Single-market focus (United States)
Funding rounds
- Apr 2025Series C$4.7M
- Jul 2023Series C$26.7M
- Oct 2022Series C$43.5M
- Jun 2020Series B$26M
Founders & team
Investors
RezVen Partners, Soundproof Ventures, Chazen Capital Partners, Jenkins Fund, AllerFund
#10
Series H · Morrisville, North Carolina · founded 2000 · 189 employees$173.4Mraised▾
Series H · Morrisville, North Carolina · founded 2000 · 189 employees
Provider of solutions for biomarker discovery, diagnostic tests, and personalized medicine. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. It also offers Quantose IR, a lab test for prediabetes assessment and treatment, and Meta IMD, a CLIA assay for inborn errors of metabolism. The company is also developing metabolomics-based clinical diagnostic tests that may improve the early detection of obesity-related metabolic diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 23k LinkedIn followers — 14.7% of this cohort's audience
Funding rounds
- Feb 2025Grant (prize money)$297.7K
- Dec 2024Series H$7.5M
- May 2024Grant (prize money)$298.3K
- Sep 2023Grant (prize money)$297.7K
Investors
Fletcher Spaght, Sevin Rosen, The Aurora Funds, Fulcrum Financial Group, Alexandria, 180 Degree Capital
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookiebotCore-JsCrazy Egg
#11
Series A · Chapel Hill, North Carolina · founded 2017 · 8 employees$8.3Mraised▾
Series A · Chapel Hill, North Carolina · founded 2017 · 8 employees
Developer of a medical device to treat arterial and venous diseases. It offers multi-mechanism thrombectomy system for the endovascular treatment of diseases which include deep vein thrombosis, pulmonary embolism, peripheral artery occlusion, and acute ischemic stroke.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Feb 2026Series A$6M
- Jul 2023Seed—
- Jan 2023Conventional Debt$2.2M
- Aug 2020Grant (prize money)$150K
Founders & team
Investors
NC State University, NIH, Harbright Ventures
#12
Series B · Durham, North Carolina · founded 2019 · 72 employees$89Mraised▾
Series B · Durham, North Carolina · founded 2019 · 72 employees
Developer of drug discovery and precision therapy platform for oncology. The company has micro-organ sphere technologies which enable rapid diagnostics, personalized drug screening, and scalable patient-derived models for immuno-oncology drug discovery.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Patents
top 21%Moat
top 21%Innovation
top 22%Funding
top 26%Talent
bottom 49%Market
bottom 46%Patents: 97 patents matched (strict assignee match) · 96 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents · Soonicorn
Innovation: 97 patents (top 19% of patent-holders) · 96 filings since 2022 vs 1 in 2017-21
Audience (LinkedIn): 7k LinkedIn followers — 4.7% of this cohort's audience
Funding rounds
- Apr 2025Series B$19.4M
- Apr 2025Conventional Debt—
- Feb 2025Grant (prize money)$2.4M
- Jul 2022Series A$19M
Founders & team
Investors
Alexandria, EQT, Mubadala, Pear VC, Google Ventures, Duke University
Tech stack
CookieyesCore-JsElementorGoogle WorkspaceHello ElementorJquery
Funding & investor landscape
$8.3Btotal disclosed funding
300companies funded
1,549disclosed rounds
2rounds last 90 days
Most active investors
Notable founders
Neil Buckley
Co-Founder & CEO · Slate Medicines
Patrick Roberts
Co-Founder & CEO · Incyclix Bio
Jay Strum
Co-Founder · Incyclix Bio
Bruce Choi
Founder & CTO · Levee Medical
Adam Irving
CEO · Levee Medical
Richard West
Co-Founder & CEO · Baebies
Vamsee Pamula
Founder and President · Baebies
Shannon Boye
Founder & Director · Atsena Therapeutics
Patrick Ritschel
Chief Executive Officer · Atsena Therapeutics
Mark Hallen
Co-Founder & CTO · Ten63
Nancy Miller-Rich
Co-Founder · Ten63
Sienna McCormick
Co-Founder & Co-CEO · Create Wellness
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research surged from 33 to 164 papers, now dominating biotechnology discovery activity.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements each jumped from 3 to 62 papers, signaling intensifying applied research.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern papers tripled from 15 to 45, reflecting sustained biosafety scrutiny across U.S. institutions.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18113
- UNIV California17975
- Regeneron Pharma16083
- Amgen10515
- Monsanto Technology9755
- UNIV Pennsylvania8528
- Harvard College7464
- UNIV Texas7384
Common questions
How many Life Sciences companies are there in North Carolina, United States?
Radar tracks 553 indexable Life Sciences companies headquartered in North Carolina, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in North Carolina, United States?
The Life Sciences companies in North Carolina, United States on this list have raised a combined $8.3B in disclosed equity funding across 300 funded companies.
Which is the highest-funded Life Sciences company in North Carolina, United States?
BioCryst is the highest-funded Life Sciences company in North Carolina, United States, with $867.3M in disclosed equity funding.
How many Life Sciences companies in North Carolina, United States are funded?
300 of the 553 Life Sciences companies in North Carolina, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in North Carolina, United States?
None of the Life Sciences companies in North Carolina, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in North Carolina, United States Life Sciences companies?
The most active investors in North Carolina, United States Life Sciences companies on this list include HHS, NCBiotech, NIH, Hatteras Venture Partners, America’s Seed Fund.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.